Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00131063" target="_blank" >RIV/00216224:14110/23:00131063 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2023.1106579" target="_blank" >10.3389/fonc.2023.1106579</a>

Result language
angličtina
Original language name
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
Original language description
The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions.
Czech name
—
Czech description
—

Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)